🇺🇸 FDA

Intelligence · Clinical Pipeline

R&D Pipeline Programs

ClinicalTrials.gov programs linked to pharma sponsors — phase, modality, and trial IDs for BD and competitive intelligence.

Programs indexed
20,548
Companies
1,769
Drugs tracked
4,797

Quick answer

NovaPharmaNews tracks 20,548 pharmaceutical R&D pipeline programs sourced from ClinicalTrials.gov, linked to sponsor companies. Each profile includes development phase, modality, trial status, NCT identifiers, and indication text — searchable for business development and competitive intelligence.

1,522 results for “solution” Clear

  1. S95012 concentrate solution for infusion 400mg/ 16 ml, Gazyvaro 1,000 mg concentrate for solution for infusion.

    The George Institute

    Soild Tumors

    phase 2 small molecule active

    1 trial

  2. SARCLISA 20mg/mL concentrate for solution for infusion.

    Pari Pharma GmbH

    Pure cell red aplasia by major ABO mismatch after allogeneic hematopoietic stem cell transplantation

    phase 2 small molecule active

    1 trial

  3. SARCLISA 20mg/mL concentrate for solution for infusion., CellProtect

    The George Institute

    Multiple myeloma

    phase 2 small molecule active

    1 trial

  4. SIROLIMUS, BEKEMV 300 mg concentrate for solution for infusion, SIROLIMUS, PREDNISONE, METHYLPREDNISOLONE SODIUM SUCCINATE, PARACETAMOL, Epysqli 300 mg concentrate for solution for infusion, PREDNISONE, DIPHENHYDRAMINE HYDROCHLORIDE, SIROLIMUS, PREDNISONE, RITUXIMAB, RITUXIMAB, ECULIZUMAB, BEKEMV 300 mg concentrate for solution for infusion, AAV9.LAMP2B, DIPHENHYDRAMINE HYDROCHLORIDE, PARACETAMOL, METHYLPREDNISOLONE SODIUM SUCCINATE, PREDNISONE, SIROLIMUS, BEKEMV 300 mg concentrate for solution for infusion

    Lacuna Pharma Pty Ltd

    Danon Disease

    phase 2 small molecule active

    1 trial

  5. SODIUM CHLORIDE SOLUTION 0.9%

    Lacuna Pharma Pty Ltd

    Acute Ischemic Stroke

    phase 2 small molecule active

    1 trial

  6. SODIUM CHLORIDE SOLUTION 0.9%, mRNA-1345

    Moderna Biotech Spain

    Respiratory syncytial virus

    phase 2 small molecule active

    1 trial

  7. SOLDESAM 0,2% gocce orali, soluzione, DARZALEX 1800 mg solution for injection, Imnovid 3 mg hard capsules, SOLDESAM 8 mg/2 ml soluzione iniettabile, Imnovid 4 mg hard capsules, Imnovid 1 mg hard capsules, Imnovid 2 mg hard capsules

    Fondazione Telethon ETS

    Multiple Myeloma relapsed and/or refractory

    phase 2 small molecule active

    1 trial

  8. SOLDESAM 0,2% gocce orali, soluzione, Pepaxti 20 mg powder for concentrate for solution for infusion, SOLDESAM 8 mg/2 ml soluzione iniettabile

    Fondazione Telethon ETS

    Relapsed Multiple Myeloma

    phase 2 small molecule active

    1 trial

  9. Saphnelo 300 mg concentrate for solution for infusion, Saphnelo placebo

    Disc Medicine

    Sjogren's disease

    phase 2 small molecule active

    1 trial

  10. Saxenda 6 mg/mL solution for injection in pre-filled pen, Saxenda 6 mg/mL solution for injection in pre-filled pen, Placebo for PF-07976016, Saxenda 6 mg/mL solution for injection in pre-filled pen

    Pfizer Australia Pty Ltd

    Obesity, Overweight

    phase 2 small molecule active

    1 trial

  11. Skyrizi 600 mg concentrate for solution for infusion

    Disc Medicine

    Inflammatory Bowel Disease (IBD)

    phase 2 small molecule active

    1 trial

  12. Skyrizi 600 mg concentrate for solution for infusion, Humira 40 mg solution for injection in pre-filled syringe

    Disc Medicine

    Inflammatory Bowel Disease (IBD)

    phase 2 small molecule active

    1 trial

  13. Sodium Chloride 0.9% w/v Intravenous Infusion BP Solution for Infusion., Cinryze 500 IU powder and solvent for solution for injection

    Disc Medicine

    aneurysmal subarachnoid hemorrhage

    phase 2 small molecule active

    1 trial

  14. Sodium Chloride 0.9%, INBRX-101 Concentrate for Solution for Infusion 50mg/ml, Respreeza 1,000 mg powder and solvent for solution for infusion.

    Sanofi-aventis Healthcare Pty Ltd

    Alpha-1 Antitrypsin Deficiency (AATD) Emphysema

    phase 2 small molecule active

    1 trial

  15. Sodium Chloride Intravenous Infusion (0.9% w/v), BP, Benlysta 400 mg powder for concentrate for solution for infusion.

    GlaxoSmithKline

    Systemic Lupus Erythematosus

    phase 2 small molecule active

    1 trial

  16. Sogroya 5 mg/1.5 mL solution for injection in pre-filled pen, Sogroya 10 mg/1.5 mL solution for injection in pre-filled pen, Sogroya 15 mg/1.5 mL solution for injection in pre-filled pen, Norditropin FlexPro, injektionsvæske, opløsning i fyldt pen

    NovoThirteen

    SGA - small for gestational age children

    phase 2 small molecule active

    1 trial

  17. Solution for injection in pre-filled syringe

    Alphapharm Pty Ltd

    Short Bowel Syndrome-associated Intestinal Failure (SBS-IF)

    phase 2 small molecule active

    1 trial

  18. Stivarga 40 mg film-coated tablets, Tevimbra 100 mg concentrate for solution for infusion, OMTX705

    Lacuna Pharma Pty Ltd

    Advanced/metastatic colorectal cancer

    phase 2 small molecule active

    1 trial

  19. Sucrose octaacetate [NF], SODIUM CHLORIDE, METHYLPREDNISOLONE VIATRIS 1 g, poudre pour solution injectable (I.V.), LIQUID PREDNISONE

    Pari Pharma GmbH

    IDIOPATHIC PULMONARY FIBROSIS

    phase 2 small molecule active

    1 trial

  20. Sustanon 250, solution injectable

    The George Institute

    Androgen deficiency, palliative care

    phase 2 small molecule active

    1 trial

  21. TAMBICICLIB 100 mg/10 mL, Solution for Injection, AZACITIDINE , TAMBICICLIB 100 mg/20 mL, Solution for Injection, VENETOCLAX

    Istituto Gentili S.r.l.

    Acute myeloid leukemia

    phase 2 small molecule active

    1 trial

  22. TAXOTERE 20 mg/1 ml concentrate for solution for infusion, Budigalimab, Livmoniplimab, Paclitaxel 6 mg/mL concentrate for solution for infusion, Gemcitabine 38 mg/mL concentrate for solution for infusion

    AbbVie Deutschland GmbH & Co. KG

    Urothelial Carcinoma, Metastatic Urothelial Carcinoma

    phase 2 small molecule active

    1 trial

  23. TAZEMETOSTAT, IMFINZI 50 mg/mL concentrate for solution for infusion.

    The George Institute

    Adult participants with metastatic or unresectable locally advanced solid tumors.

    phase 2 small molecule active

    1 trial

  24. TEDOPI, LIBTAYO 350 mg concentrate for solution for infusion., Armisarte 25 mg/ml concentrate for solution for infusion

    Fondazione Telethon ETS

    NSCLC non-small cell lung cancer

    phase 2 small molecule active

    1 trial

Frequently asked questions

What is the NovaPharmaNews pipeline directory?

It is a searchable index of 20,548 clinical development programs grouped by sponsor company, with phase (Phase 1–3), modality, trial status, and linked NCT IDs from ClinicalTrials.gov.

Where does pipeline data come from?

Program records are derived from ClinicalTrials.gov and linked to NovaPharmaNews company profiles. Trial status and phase reflect registry data at last sync — verify on ClinicalTrials.gov before investment or partnering decisions. See our data sources page for attribution.

How do I find pipeline programs by company or phase?

Use the search box to match program name, indication, company name, or slug. Results are ordered with late-stage (Phase 3) programs first. Open any row to view the full program profile under its sponsor company.

Data attribution and licensing: Data sources